SBT-100
Pancreatic Cancer
Key Facts
About Singh Biotechnology
Singh Biotechnology, founded in 2008 and based in San Diego, is a private biotechnology company developing therapeutics using its disruptive single-domain antibody (sdAb) platform. This technology enables the creation of small, stable antibodies that can cross cell membranes and the blood-brain barrier to target intracellular disease drivers like STAT3, KRAS, and TNF-alpha. The company is pre-revenue and in the pre-clinical/early clinical stage, with its most advanced program, SBT-100, holding orphan drug designations for two cancer indications. Its business model is centered on advancing its proprietary pipeline toward clinical validation and potential partnerships.
View full company profileAbout Singh Biotechnology
Singh Biotechnology, founded in 2008 and based in San Diego, is a private biotechnology company developing therapeutics using its disruptive single-domain antibody (sdAb) platform. This technology enables the creation of small, stable antibodies that can cross cell membranes and the blood-brain barrier to target intracellular disease drivers like STAT3, KRAS, and TNF-alpha. The company is pre-revenue and in the pre-clinical/early clinical stage, with its most advanced program, SBT-100, holding orphan drug designations for two cancer indications. Its business model is centered on advancing its proprietary pipeline toward clinical validation and potential partnerships.
View full company profileTherapeutic Areas
Other Pancreatic Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Ampligen® (rintatolimod) | AIM ImmunoTech | Early Access Program |
| HBM9027 | Harbour BioMed | Phase 1 |
| Small-Molecule Therapeutic | AIkido Labs | Pre-clinical |
| AHPBA IRE Registry | AngioDynamics | Post-Market Registry |
| SIMBs + Immunotherapy | Advanced Microbubbles | Pre-clinical |
| CLS-014 | CLS Therapeutics | Pre-clinical |
| SOMA Platform | Coherence Neuro | Pre-clinical |
| NP-G2-044 | Novita Pharmaceuticals | Phase 2a |
| Pritumumab (PTB) | Nascent Biotech | Phase II (Planned) |
| Pancreatic Cancer Test | Mosaique Diagnostic | Development |
| Iontophoretic System | Continuity Biosciences | Pre-clinical |
| Lixumistat (IM156) | ImmunoMet Therapeutics | Phase 1b |